Type I Interferon Potentiates IgA Immunity to Respiratory Syncytial Virus Infection During Infancy

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Hijano, Diego R ^a   Siefker, David T ^b   Shrestha, Bishwas ^c   Jaligama, Sridhar ^c   Vu, Luan D ^b   Tillman, Heather ^a   Finkelstein, David ^a   Saravia, Jordy ^c   You, Dahui ^c   Cormier, Stephania A ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN A; INTERFERON; PALIVIZUMAB;

ANIMAL; BAGG ALBINO MOUSE; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ANIMALS; B-CELL ACTIVATING FACTOR; FLOW CYTOMETRY; IMMUNOGLOBULIN A; INTERFERON TYPE I; MICE; MICE, INBRED BALB C; PALIVIZUMAB; REAL-TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 85050616967     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-29456-w     Document Type: Article

References (57)

1. Hall, C. B., Simoes, E. A. & Anderson, L. J. Clinical and epidemiologic features of respiratory syncytial virus. Current topics in microbiology and immunology 372, 39–57, 10.1007/978-3-642-38919-1_2 (2013).
2. Hall, C. B. et al. The burden of respiratory syncytial virus infection in young children. The New England journal of medicine 360, 588–598, 10.1056/NEJMoa0804877 (2009).
3. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet (London, England) 375, 1545–1555, 10.1016/s0140-6736(10)60206-1 (2010).
4. Stein, R. T. et al. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatric pulmonology. 10.1002/ppul.23570 (2016).
5. Wang, E. E., Law, B. J. & Stephens, D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. The Journal of pediatrics 126, 212–219 (1995).
6. Boyce, T. G., Mellen, B. G., Mitchel, E. F. Jr., Wright, P. F. & Griffin, M. R. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. The Journal of pediatrics 137, 865–870, 10.1067/mpd.2000.110531 (2000).
7. Hislop, A. A. & Haworth, S. G. Airway size and structure in the normal fetal and infant lung and the effect of premature delivery and artificial ventilation. The American review of respiratory disease 140, 1717–1726, 10.1164/ajrccm/140.6.1717 (1989).
8. Forster, J., Streckert, H. J. & Werchau, H. The humoral immune response of children and infants to an RSV infection: its maturation and association with illness. Klinische Padiatrie 207, 313–316, 10.1055/s-2008-1046559 (1995).
9. Wilczynski, J., Lukasik, B., Torbicka, E., Tranda, I. & Brzozowska-Binda, A. The immune response of small children by antibodies of different classes to respiratory syncytial virus (RSV) proteins. Acta microbiologica Polonica 43, 369–379 (1994).
10. Caballero, M. T. et al. TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization. The Journal of Clinical Investigation 125, 571–582, 10.1172/JCI75183 (2015).
11. Adkins, B., Leclerc, C. & Marshall-Clarke, S. Neonatal adaptive immunity comes of age. Nat Rev Immunol 4, 553–564, 10.1038/nri1394 (2004).
12. Tasker, L., Lindsay, R. W. B., Clarke, B. T., Cochrane, D. W. R. & Hou, S. Infection of mice with respiratory syncytial virus during neonatal life primes for enhanced antibody and T cell responses on secondary challenge. Clinical and Experimental Immunology 153, 277–288, 10.1111/j.1365-2249.2008.03591.x (2008).
13. You, D., Saravia, J., Siefker, D., Shrestha, B. & Cormier, S. A. Crawling with Virus: Translational Insights from a Neonatal Mouse Model on the Pathogenesis of Respiratory Syncytial Virus in Infants. Journal of virology 90, 2–4, 10.1128/JVI.01026-15 (2015).
14. Cormier, S. A., You, D. & Honnegowda, S. The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert review of anti-infective therapy 8, 1371–1380, 10.1586/eri.10.125 (2010).
15. You, D., Siefker, D. T., Shrestha, B., Saravia, J. & Cormier, S. A. Building a better neonatal mouse model to understand infant respiratory syncytial virus disease. Respiratory research 16, 91, 10.1186/s12931-015-0244-0 (2015).
16. Harker, J. A., Yamaguchi, Y., Culley, F. J., Tregoning, J. S. & Openshaw, P. J. M. Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Are Dependent on Cells of the Innate Immune System. Journal of virology 88, 604–611, 10.1128/JVI.02620-13 (2014).
17. McIntosh, K. Interferon in nasal secretions from infants with viral respiratory tract infections. The Journal of pediatrics 93, 33–36 (1978).
18. Hall, C. B., Douglas, R. G. Jr., Simons, R. L. & Geiman, J. M. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. The Journal of pediatrics 93, 28–32 (1978).
19. Roberts, N. J. Jr., Hiscott, J. & Signs, D. J. The limited role of the human interferon system response to respiratory syncytial virus challenge: analysis and comparison to influenza virus challenge. Microbial pathogenesis 12, 409–414 (1992).
20. Bossert, B., Marozin, S. & Conzelmann, K. K. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. Journal of virology 77, 8661–8668 (2003).
21. Spann, K. M., Tran, K. C., Chi, B., Rabin, R. L. & Collins, P. L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. Journal of virology 78, 4363–4369 (2004).
22. Marr, N. et al. Attenuation of Respiratory Syncytial Virus–Induced and RIG-I–Dependent Type I IFN Responses in Human Neonates and Very Young Children. The Journal of Immunology 192, 948–957 (2014).
23. Cormier, S. A. et al. Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol 88, 9350–9360, 10.1128/jvi.00818-14 (2014).
24. Remot, A. et al. Flt3 ligand improves the innate response to respiratory syncytial virus and limits lung disease upon RSV reexposure in neonate mice. European journal of immunology 46, 874–884, 10.1002/eji.201545929 (2016).
25. Kollmann, T. R. & Marchant, A. Towards Predicting Protective Vaccine Responses in the Very Young. Trends in immunology 37, 523–534, 10.1016/j.it.2016.05.005 (2016).
26. Gill, N., Wlodarska, M. & Finlay, B. B. The future of mucosal immunology: studying an integrated system-wide organ. Nature immunology 11, 558–560, 10.1038/ni0710-558 (2010).
27. McGhee, J. R. & Fujihashi, K. Inside the mucosal immune system. PLoS biology 10, e1001397, 10.1371/journal.pbio.1001397 (2012).
28. Habibi, M. S. et al. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. American journal of respiratory and critical care medicine 191, 1040–1049, 10.1164/rccm.201412-2256OC (2015).
29. Bagga, B. et al. Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults. The Journal of infectious diseases 212, 1719–1725, 10.1093/infdis/jiv281 (2015).
30. Vissers, M., Ahout, I. M., de Jonge, M. I. & Ferwerda, G. Mucosal IgG Levels Correlate Better with Respiratory Syncytial Virus Load and Inflammation than Plasma IgG Levels. Clinical and vaccine immunology: CVI 23, 243–245, 10.1128/cvi.00590-15 (2015).
31. Fujkuyama, Y. et al. Novel vaccine development strategies for inducing mucosal immunity. Expert review of vaccines 11, 367–379, 10.1586/erv.11.196 (2012).
32. Staats, H. F. et al. Mucosal immunity to infection with implications for vaccine development. Current opinion in immunology 6, 572–583 (1994).
33. Fujihashi, K. & Kiyono, H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends in immunology 30, 334–343, 10.1016/j.it.2009.04.004 (2009).
34. Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian of B cell identity and function. Nat Immunol 8, 463–470 (2007).
35. von Bulow, G. U., van Deursen, J. M. & Bram, R. J. Regulation of the T-independent humoral response by TACI. Immunity 14, 573–582 (2001).
36. Shulga-Morskaya, S. et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. Journal of immunology (Baltimore, Md.: 1950) 173, 2331–2341 (2004).
37. Cerutti, A., Qiao, X. & He, B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunology and cell biology 83, 554–562, 10.1111/j.1440-1711.2005.01389.x (2005).
38. O’Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. The Journal of experimental medicine 199, 91–98, 10.1084/jem.20031330 (2004).
39. Eichinger, K. M. et al. Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice. Respiratory Research 16, 122, 10.1186/s12931-015-0282-7 (2015).
40. Mejias, A. et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrobial agents and chemotherapy 48, 1811–1822 (2004).
41. Mejias, A. et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrobial agents and chemotherapy 49, 4700–4707, 10.1128/aac.49.11.4700-4707.2005 (2005).
42. Tripp, R. A., Power, U. F., Openshaw, P. J. M. & Kauvar, L. M. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. Journal of virology 92, https://doi.org/10.1128/jvi.01302-17 (2018).
43. Capella, C. et al. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. The Journal of infectious diseases 216, 1398–1406, 10.1093/infdis/jix489 (2017).
44. Bouaziz, J. D. et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proceedings of the National Academy of Sciences of the United States of America 104, 20878–20883, 10.1073/pnas.0709205105 (2007).
45. Khan, W. N. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. Journal of immunology (Baltimore, Md.: 1950) 183, 3561–3567, 10.4049/jimmunol.0800933 (2009).
46. Vinuesa, C. G. & Chang, P.-P. Innate B cell helpers reveal novel types of antibody responses. Nat Immunol 14, 119–126 (2013).
47. Reed, J. L. et al. Innate immune signals modulate antiviral and polyreactive antibody responses during severe respiratory syncytial virus infection. The Journal of infectious diseases 199, 1128–1138, 10.1086/597386 (2009).
48. McNamara, P. S. et al. Respiratory syncytial virus infection of airway epithelial cells, in vivo and in vitro, supports pulmonary antibody responses by inducing expression of the B cell differentiation factor BAFF. Thorax 68, 76–81, 10.1136/thoraxjnl-2012-202288 (2013).
49. Kanswal, S., Katsenelson, N., Selvapandiyan, A., Bram, R. J. & Akkoyunlu, M. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. Journal of immunology (Baltimore, Md.: 1950) 181, 976–990 (2008).
50. Collins, P. L. & Graham, B. S. Viral and host factors in human respiratory syncytial virus pathogenesis. Journal of virology 82, 2040–2055, 10.1128/jvi.01625-07 (2008).
51. Chu, H. Y. et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. The Journal of infectious diseases 210, 1582–1589, 10.1093/infdis/jiu316 (2014).
52. Walsh, E. E. & Falsey, A. R. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. The Journal of infectious diseases 190, 373–378, 10.1086/421524 (2004).
53. Smit, J. J., Rudd, B. D. & Lukacs, N. W. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. The Journal of experimental medicine 203, 1153–1159, 10.1084/jem.20052359 (2006).
54. Asanuma, H. et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. Journal of immunological methods 202, 123–131 (1997).
55. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.) 25, 402–408, 10.1006/meth.2001.1262 (2001).
56. Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics 14, 128, 10.1186/1471-2105-14-128 (2013).
57. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (Oxford, England) 4, 249–264, 10.1093/biostatistics/4.2.249 (2003).